Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Kyndryl Holdings Inc (KD) Price & Performance

Inovio Pharmaceuticals IncTrade
Kyndryl Holdings IncTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Kyndryl Holdings Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Kyndryl Holdings Inc trades at $12.94 (market cap $2.91B). The key difference: Kyndryl Holdings Inc is far larger — about 37× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

INOKD
Market Cap
$78.55M$2.91B
Sector
HealthTechnology
52-Week High
$2.87$33.14
52-Week Low
$0.66$10.59
Enterprise Value
$49.56M$5.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

Kyndryl Holdings Inc

Kyndryl (KD) trades at $12.87, down 5.58% on the day, with a neutral technical signal and mixed earnings history. The company reported a net income of $252 million in 2025, reversing prior losses, and maintains strong operating cash flow of $942 million. Recent news includes an acquisition to boost AI services and Q1 2027 results showing a revenue miss but an EBITDA beat.

The stock presents a cautious opportunity with a consensus price target of $13.50, offering modest upside. Risks include inconsistent earnings, high debt levels, and ongoing investigations. Analyst sentiment is predominantly hold, reflecting uncertainty amid strategic shifts toward growth areas like AI and cloud partnerships.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Kyndryl Holdings Inc

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.

Read more on KD